Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

US-based fibrosis and cancer therapy developer Galecto has filed to raise up to $100m initial public offering that would provide exits for pharmaceutical firms Merck Group, Bristol Myers-Squibb (BMS) and Novo. Galecto is working on small molecule therapeutics for diseases such as cancer and fibrosis, a condition where connective tissue becomes scarred. The IPO proceeds…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.